Showing 1 - 10 of 725
Persistent link: https://www.econbiz.de/10011696444
Persistent link: https://www.econbiz.de/10011696445
Persistent link: https://www.econbiz.de/10011696583
Persistent link: https://www.econbiz.de/10011696649
Long waiting lines are a common feature and a major concern in many public health care delivery systems. The waiting lines are often characterized as inefficient, because they are a burden to patients without generating any gains for providers. There is an ongoing debate in Germany regarding the...
Persistent link: https://www.econbiz.de/10011632295
In Germany, private health insurance covers more innovative and costly treatments than public insurance. Moreover, privately insured individuals are treated preferentially by doctors. In this article, I use subjective health data to examine whether these superior features of private insurance...
Persistent link: https://www.econbiz.de/10011674043
This study examines whether Seguro Popular, a free-of-charge publicly provided health insurance program for otherwise uninsured households, crowded-out private transfers in Mexico. Using data from the National Household Income and Expenditure Survey, the effects of Seguro Popular are identified...
Persistent link: https://www.econbiz.de/10011994303
The Extended Medicare Safety Net (EMSN) in Australia was designed to provide financial assistance to patients with high out-of-pocket (OOP) costs for medical treatment. The EMSN works on a calendar year basis. Once a patient incurs a specified amount of OOP costs, the EMSN provides additional...
Persistent link: https://www.econbiz.de/10014533851
In this paper, we examine trends in provider fees charged, government expenditure on private out-of-hospital medical services, and out of pocket costs following policy changes intended to reduce government expenditure. We examine the experience of a high-need patient group: people diagnosed with...
Persistent link: https://www.econbiz.de/10014533939
A non-trivial fraction of people cannot afford to buy pharmaceutical products at unregulated market prices. Therefore, the paper analyzes the public insurance of the pharmaceutical products in terms of price controls and the socially optimal third-degree price discrimination. It characterizes...
Persistent link: https://www.econbiz.de/10012179830